Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: Mar 31, 2023

TORRANCE, Calif., March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended December 31, 2022 and an update on recent activities.